JP2020011993A - Skin external application agent - Google Patents
Skin external application agent Download PDFInfo
- Publication number
- JP2020011993A JP2020011993A JP2019181614A JP2019181614A JP2020011993A JP 2020011993 A JP2020011993 A JP 2020011993A JP 2019181614 A JP2019181614 A JP 2019181614A JP 2019181614 A JP2019181614 A JP 2019181614A JP 2020011993 A JP2020011993 A JP 2020011993A
- Authority
- JP
- Japan
- Prior art keywords
- skin
- drug
- external application
- steroidal anti
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 22
- DGYSDXLCLKPUBR-SLPNHVECSA-N prednisolone valerate acetate Chemical group C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(C)=O)(OC(=O)CCCC)[C@@]1(C)C[C@@H]2O DGYSDXLCLKPUBR-SLPNHVECSA-N 0.000 claims abstract description 7
- 229950008480 prednisolone valerate acetate Drugs 0.000 claims abstract description 7
- 150000002148 esters Chemical class 0.000 claims description 16
- 238000002360 preparation method Methods 0.000 claims description 16
- 235000011187 glycerol Nutrition 0.000 claims description 10
- 239000006071 cream Substances 0.000 claims description 7
- 229960005205 prednisolone Drugs 0.000 claims description 6
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims description 6
- 230000000699 topical effect Effects 0.000 claims description 5
- 201000004624 Dermatitis Diseases 0.000 abstract description 16
- 239000003795 chemical substances by application Substances 0.000 abstract description 7
- 239000002294 steroidal antiinflammatory agent Substances 0.000 abstract description 4
- 229940124599 anti-inflammatory drug Drugs 0.000 description 15
- 230000003637 steroidlike Effects 0.000 description 15
- 229940079593 drug Drugs 0.000 description 14
- 239000003814 drug Substances 0.000 description 14
- -1 fatty acid ester Chemical class 0.000 description 11
- 208000024891 symptom Diseases 0.000 description 9
- 239000002260 anti-inflammatory agent Substances 0.000 description 8
- 235000014113 dietary fatty acids Nutrition 0.000 description 7
- 229930195729 fatty acid Natural products 0.000 description 7
- 239000000194 fatty acid Substances 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 206010070834 Sensitisation Diseases 0.000 description 4
- FPVRUILUEYSIMD-RPRRAYFGSA-N [(8s,9r,10s,11s,13s,14s,16r,17r)-9-fluoro-11-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(OC(C)=O)[C@@]1(C)C[C@@H]2O FPVRUILUEYSIMD-RPRRAYFGSA-N 0.000 description 4
- FBRAWBYQGRLCEK-UHFFFAOYSA-N [17-(2-chloroacetyl)-9-fluoro-10,13,16-trimethyl-3,11-dioxo-7,8,12,14,15,16-hexahydro-6h-cyclopenta[a]phenanthren-17-yl] butanoate Chemical compound C1CC2=CC(=O)C=CC2(C)C2(F)C1C1CC(C)C(C(=O)CCl)(OC(=O)CCC)C1(C)CC2=O FBRAWBYQGRLCEK-UHFFFAOYSA-N 0.000 description 4
- 229960005465 clobetasone butyrate Drugs 0.000 description 4
- 238000013329 compounding Methods 0.000 description 4
- ALEXXDVDDISNDU-JZYPGELDSA-N cortisol 21-acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ALEXXDVDDISNDU-JZYPGELDSA-N 0.000 description 4
- 229960003657 dexamethasone acetate Drugs 0.000 description 4
- 229930195733 hydrocarbon Natural products 0.000 description 4
- 150000002430 hydrocarbons Chemical class 0.000 description 4
- 229960001067 hydrocortisone acetate Drugs 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000008313 sensitization Effects 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 3
- FBRAWBYQGRLCEK-AVVSTMBFSA-N Clobetasone butyrate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CCl)(OC(=O)CCC)[C@@]1(C)CC2=O FBRAWBYQGRLCEK-AVVSTMBFSA-N 0.000 description 3
- 206010012438 Dermatitis atopic Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 201000008937 atopic dermatitis Diseases 0.000 description 3
- 229960001146 clobetasone Drugs 0.000 description 3
- 229960003957 dexamethasone Drugs 0.000 description 3
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 3
- 238000001647 drug administration Methods 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 229960000890 hydrocortisone Drugs 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- DMNJPLQUXVZFSJ-UHFFFAOYSA-N 2-chloro-1,3,5-trinitrobenzene Chemical compound [O-][N+](=O)C1=CC([N+]([O-])=O)=C(Cl)C([N+]([O-])=O)=C1.[O-][N+](=O)C1=CC([N+]([O-])=O)=C(Cl)C([N+]([O-])=O)=C1 DMNJPLQUXVZFSJ-UHFFFAOYSA-N 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 239000003002 pH adjusting agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 230000001235 sensitizing effect Effects 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- FLPJVCMIKUWSDR-UHFFFAOYSA-N 2-(4-formylphenoxy)acetamide Chemical compound NC(=O)COC1=CC=C(C=O)C=C1 FLPJVCMIKUWSDR-UHFFFAOYSA-N 0.000 description 1
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- HBTAOSGHCXUEKI-UHFFFAOYSA-N 4-chloro-n,n-dimethyl-3-nitrobenzenesulfonamide Chemical compound CN(C)S(=O)(=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 HBTAOSGHCXUEKI-UHFFFAOYSA-N 0.000 description 1
- 208000019300 CLIPPERS Diseases 0.000 description 1
- YASYEJJMZJALEJ-UHFFFAOYSA-N Citric acid monohydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- BTFJIXJJCSYFAL-UHFFFAOYSA-N arachidyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 229940082500 cetostearyl alcohol Drugs 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 229940074979 cetyl palmitate Drugs 0.000 description 1
- 208000021930 chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000002951 depilatory effect Effects 0.000 description 1
- 229940031578 diisopropyl adipate Drugs 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229960000735 docosanol Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- PXDJXZJSCPSGGI-UHFFFAOYSA-N hexadecanoic acid hexadecyl ester Natural products CCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC PXDJXZJSCPSGGI-UHFFFAOYSA-N 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 229940056211 paraffin Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000036620 skin dryness Effects 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229940012831 stearyl alcohol Drugs 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
関連出願の相互参照
本出願は、２０１７年６月２８日出願の日本特願２０１７−１２６１４２号の優先権を主張し、それらの全記載は、ここに特に開示として援用される。
This application claims the priority of Japanese Patent Application No. 2017-126142 filed on Jun. 28, 2017, the entire description of which is incorporated herein by reference.
本発明は、ステロイド性抗炎症薬を用いた皮膚外用塗布剤に関し、特に皮膚炎の治療とその後の再発を抑制する皮膚外用塗布剤に関する。 The present invention relates to a topical skin application using a steroidal anti-inflammatory drug, and more particularly, to a topical skin application for treating dermatitis and suppressing subsequent recurrence.
プレドニゾロン吉草酸エステル酢酸エステル、ヒドロコルチゾン酢酸エステル、デキサメタゾン酢酸エステルおよびクロベタゾン酪酸エステル等のステロイド性抗炎症薬は、湿疹、皮膚炎、皮膚掻痒症等、皮膚疾患の治療に広く用いられている。 Steroidal anti-inflammatory drugs such as prednisolone valerate acetate, hydrocortisone acetate, dexamethasone acetate and clobetasone butyrate are widely used for the treatment of skin diseases such as eczema, dermatitis and pruritus cutaneous.
しかし、薬剤の投与期間中はステロイド性抗炎症薬の作用により高い治療効果が認められるが、薬剤の使用を終了すると皮膚症状が再発するという問題があり、患者は症状が改善された後も暫くは薬剤を投与し続ける必要があった。
一般に、ステロイド性抗炎症薬を用いた治療では、症状の改善とともに、投与量を減らす、又は、徐々に弱い薬理活性の薬剤へ切り替えていくことが理想的であるが、上記のような実情が、長期に亘るステロイド性抗炎症薬の常用や、薬理活性の高いステロイド性抗炎症薬への切替えを招く要因の一つとなっており、皮膚への負担や副作用が懸念されている。
従来、薬剤投与期間中に皮膚炎を抑える効果の高い組成物は種々提案されてきたが、薬剤の使用を終了した後の再発防止に効果のある薬剤組成は知られていない。
However, steroidal anti-inflammatory drugs have a high therapeutic effect during the administration period of the drug, but there is a problem that skin symptoms recur when the drug is stopped, and patients have been treated for a while after the symptoms have improved. Needed to continue to administer the drug.
In general, in treatment with steroidal anti-inflammatory drugs, it is ideal to reduce the dosage or gradually switch to a weakly pharmacologically active drug with improvement of the symptoms. It is one of the factors that cause long-term regular use of steroidal anti-inflammatory drugs and switching to steroidal anti-inflammatory drugs having high pharmacological activity, and there is a concern about burden on the skin and side effects.
Conventionally, various compositions having a high effect of suppressing dermatitis during the drug administration period have been proposed, but no drug composition effective for preventing recurrence after the use of the drug is finished is not known.
本発明は、上記事情を鑑みたものであり、薬剤の投与を終了した後も、皮膚炎の再発を抑制することが可能な皮膚外用塗布剤を提供することを目的とする。 The present invention has been made in view of the above circumstances, and an object of the present invention is to provide a skin external application agent capable of suppressing recurrence of dermatitis even after administration of a drug is completed.
本発明者らは、薬剤の投与期間中の抗炎症効果だけでなく、投与終了後の再発抑制効果に着目し、鋭意検討を重ねた結果、ステロイド性抗炎症薬にグリセリンを高濃度で配合した皮膚外用塗布剤が、薬剤の投与を終了した後の皮膚炎の再発を抑制する効果があることを見出した。 The present inventors focused on not only the anti-inflammatory effect during the administration period of the drug but also the recurrence inhibitory effect after the administration was completed, and as a result of intensive studies, glycerin was added to the steroidal anti-inflammatory drug at a high concentration. The present inventors have found that an external preparation for skin has an effect of suppressing recurrence of dermatitis after administration of the drug.
すなわち、本発明は、ステロイド性抗炎症薬および、グリセリンを３０〜４０重量％含有することを特徴とする。 That is, the present invention is characterized by containing 30 to 40% by weight of a steroidal anti-inflammatory drug and glycerin.
本発明によれば、ステロイド性抗炎症薬および、グリセリンを３０〜４０重量％を含有することによって、皮膚炎の症状を治癒するだけでなく、薬剤の投与を終了した後の、症状の再発を抑制する。そのため、薬剤の投与期間及び投与量を必要最低限に抑えることが可能であり、患者への負担の少ない皮膚外用塗布剤を提供することができる。 According to the present invention, by containing a steroidal anti-inflammatory drug and glycerin in an amount of 30 to 40% by weight, not only can the symptoms of dermatitis be cured, but also the recurrence of the symptoms after the administration of the drug is terminated. Suppress. Therefore, it is possible to minimize the administration period and dosage of the drug, and it is possible to provide a skin external application agent that places less burden on the patient.
本発明の皮膚外用塗布剤は、ステロイド性抗炎症薬、グリセリン、高級アルコール、脂肪酸エステル、炭化水素、乳化剤を配合し、皮膚に塗布するために適当な粘性を有するクリーム剤であって、医薬品、医薬部外品等の用途に適用可能である。 The external application preparation for skin of the present invention is a steroidal anti-inflammatory drug, glycerin, higher alcohol, fatty acid ester, hydrocarbon, and an emulsifier, and is a cream having a suitable viscosity for application to the skin. It is applicable to quasi-drugs and other uses.
ステロイド性抗炎症薬は、皮膚の炎症症状を抑えるものであり、その機能と作用の強さによって「最も強い」「とても強い」「強い」「中程度」「弱い」等の５段階に分類されており、それぞれ投与期間と投与量の目安が定められている。
本実施形態においては、ステロイド性抗炎症薬として「中程度」に分類されるプレドニゾロンまたはそのエステル、ヒドロコルチゾンまたはそのエステル、デキサメタゾンまた
はそのエステル、クロベタゾンまたはそのエステルなどを用いることが出来る。
ここで、エステルは、それぞれの化合物が形成する物であれば何でもよいが、例えば…
プレドニゾロンまたはそのエステルとしてはプレドニゾロン吉草酸エステル酢酸エステルが好ましく、ヒドロコルチゾンまたはそのエステルとしてはヒドロコルチゾン酢酸エステルが好ましく、デキサメタゾンまたはそのエステルとしてはデキサメタゾン酢酸エステルが好ましく、クロベタゾンまたはそのエステルとしてはクロベタゾン酪酸エステルが好ましい。
プレドニゾロン吉草酸エステル酢酸エステルはリビメックスコーワクリーム（商標）、ヒドロコルチゾン酢酸エステルはオイラックスＡ(商標)、デキサメタゾン酢酸エステルはエマゼン（商標）、クロベタゾン酪酸エステルはキンダベート（商標）などに有効成分として含まれている。
また、症状の重症度に合わせてより強いステロイド性抗炎症薬を用いてもよい。
Steroidal anti-inflammatory drugs are used to suppress skin inflammatory symptoms, and are classified into five levels such as "strongest", "very strong", "strong", "moderate", and "weak" according to their function and strength of action. In each case, the administration period and the target dose are set.
In the present embodiment, prednisolone or an ester thereof, hydrocortisone or an ester thereof, dexamethasone or an ester thereof, clobetasone or an ester thereof, and the like classified as “moderate” can be used as the steroidal anti-inflammatory drug.
Here, the ester may be anything as long as each compound is formed.
Prednisolone or its ester is preferably prednisolone valerate acetate, hydrocortisone or its ester is preferably hydrocortisone acetate, dexamethasone or its ester is preferably dexamethasone acetate, and clobetasone or its ester is clobetasone butyrate. .
Prednisolone valerate acetate is contained as an active ingredient in Rivimex Kowa Cream (trademark), hydrocortisone acetate is Eilax A (trademark), dexamethasone acetate is emamazen (trademark), and clobetasone butyrate is kindabate (trademark). I have.
Also, stronger steroidal anti-inflammatory drugs may be used depending on the severity of the condition.
ステロイド性抗炎症薬の配合量（含有量）については、皮膚外用塗布剤における一般的に最適とされる配合量であることが望ましい。
プレドニゾロンまたはそのエステルの配合量は、例えば０．０１〜０．３重量％であり、好ましくは０．０７５〜０．２５重量％であり、ヒドロコルチゾンまたはそのエステルの配合量は、例えば０．１〜１．０重量％であり、好ましくは０．２５〜０．７５重量％であり、デキサメタゾンまたはそのエステルの配合量は、例えば０．０１〜０．０６重量％であり、好ましくは０．０１２５〜０．０４重量％であり、クロベタゾンまたはそのエステルの配合量は、例えば０．０１〜０．０１重量％であり、好ましくは０．０２５〜０．０７５％重量％である。
The compounding amount (content) of the steroidal anti-inflammatory drug is desirably the compounding amount that is generally optimized in a skin external application.
The amount of prednisolone or its ester is, for example, 0.01 to 0.3% by weight, preferably 0.075 to 0.25% by weight, and the amount of hydrocortisone or its ester is, for example, 0.1 to 0.3% by weight. 1.0% by weight, preferably 0.25 to 0.75% by weight, and the compounding amount of dexamethasone or an ester thereof is, for example, 0.01 to 0.06% by weight, preferably 0.0125 to 0.04% by weight, and the compounding amount of clobetasone or an ester thereof is, for example, 0.01 to 0.01% by weight, and preferably 0.025 to 0.075% by weight.
本発明の皮膚外用塗布剤に配合されるステロイド性抗炎症薬としては、０．０７５〜０．２５重量％のプレドニゾロン吉草酸エステル酢酸エステル、０．２５〜０．７５重量％のヒドロコルチゾン酢酸エステル、０．０１２５〜０．０４重量％のデキサメタゾン酢酸エステルまたは０．０２５〜０．０７５％重量％のクロベタゾン酪酸エステルが最も好ましい。 Examples of the steroidal anti-inflammatory drug to be incorporated in the external application for skin of the present invention include 0.075 to 0.25% by weight of prednisolone valerate acetate, 0.25 to 0.75% by weight of hydrocortisone acetate, Most preferred is 0.0125-0.04% by weight dexamethasone acetate or 0.025-0.075% by weight clobetasone butyrate.
グリセリンは保湿成分として知られているが、本発明においては保湿効果の他に、薬剤の使用終了後の再発を防止するために用いている。本発明の皮膚外用塗布剤におけるグリセリンの最適な配合量は、３０重量％〜４０重量％である。３０重量％未満では、皮膚外用塗布剤投与終了後の症状の再発抑制効果が十分に得られず、４０重量％を超えると、塗布後のべたつきによる不快感から、患者が使用を拒むおそれがある。
なお、保湿剤としては、グリセリン以外の多価アルコール、例えば１，３−ブチレングリコール、プロピレングリコール、Ｄ−ソルビトールや、ヒアルロン酸等を配合してもよい。
Glycerin is known as a moisturizing component. In the present invention, glycerin is used in addition to the moisturizing effect to prevent recurrence after use of the drug. The optimal blending amount of glycerin in the skin external application preparation of the present invention is 30% by weight to 40% by weight. When the amount is less than 30% by weight, the effect of suppressing the recurrence of symptoms after the administration of the external preparation for skin is not sufficiently obtained, and when the amount exceeds 40% by weight, the patient may refuse to use due to discomfort due to stickiness after application. .
As the humectant, a polyhydric alcohol other than glycerin, for example, 1,3-butylene glycol, propylene glycol, D-sorbitol, hyaluronic acid, or the like may be blended.
高級アルコールは、クリーム剤の粘度を調整するために配合してある。本実施形態においては、高級アルコールとしてセトステアリルアルコールと、オクチルドデカノールを用いたが、他の高級アルコール、例えば、セタノール、ステアリルアルコール、ベヘニルアルコール等を用いてもよい。 The higher alcohol is blended to adjust the viscosity of the cream. In the present embodiment, as the higher alcohol, cetostearyl alcohol and octyldodecanol are used, but other higher alcohols, for example, cetanol, stearyl alcohol, behenyl alcohol and the like may be used.
脂肪酸エステルは、ステロイド性抗炎症剤を溶解するため、又は、溶解し易くするために配合してある。本実施形態においては、脂肪酸エステルとしてアジピン酸ジイソプロピルを用いたが、パルミチン酸イソプロピル、パルミチン酸セチル等、ステロイド性抗炎症剤を溶解可能なものであればよい。 Fatty acid esters are formulated to dissolve or facilitate dissolution of the steroidal anti-inflammatory agent. In the present embodiment, diisopropyl adipate is used as the fatty acid ester, but any material capable of dissolving a steroidal anti-inflammatory agent, such as isopropyl palmitate and cetyl palmitate, may be used.
炭化水素は、油膜を形成し、皮膚の乾燥を防ぐために配合してある。本実施形態においては、炭化水素として流動パラフィンを用いたが、例えば、パラフィン、ワセリン、スク
ワラン等の他の炭化水素を用いてもよい。
Hydrocarbons are formulated to form an oil slick and prevent skin dryness. In the present embodiment, liquid paraffin is used as the hydrocarbon, but other hydrocarbons such as paraffin, vaseline, and squalane may be used.
乳化剤としては、ポリオキシエチレンベヘニルエーテルとグリセリン脂肪酸エステルを用いたが、水相と油相とを乳化してクリーム剤とすることが可能であれば、例えば、ポリエチレングリコール脂肪酸エステル、ポリオキシエチレン硬化ヒマシ油、ソルビタン脂肪酸エステル等の他の乳化剤を用いてもよい。 As the emulsifier, polyoxyethylene behenyl ether and glycerin fatty acid ester were used, but if it is possible to emulsify the aqueous phase and oil phase into a cream, for example, polyethylene glycol fatty acid ester, polyoxyethylene cured Other emulsifiers such as castor oil and sorbitan fatty acid esters may be used.
本発明の皮膚外用塗布剤には、上記の他に、ｐＨ調節剤や、防腐剤を配合することが望ましい。ｐＨ調節剤は、本実施形態においては、クエン酸水和物及びクエン酸ナトリウム水和物を配合しているが、例えば、乳酸、リンゴ酸、リン酸、炭酸、酒石酸、又はこれらの塩等の他のｐＨ調節剤を用いてもよい。防腐剤は、本実施形態においては、パラオキシ安息香酸メチル、パラオキシ安息香酸プロピルを配合しているが、例えば、パラオキシ安息香酸ブチル、フェノキシエタノール等の他の防腐剤を用いてもよい。
また、一般的なクリーム剤に配合される油脂として、オリーブ油、大豆油等の植物油や、ステアリン酸等の高級脂肪酸、ミツロウ等のロウ類等を配合してもよい。
In addition to the above, a pH adjusting agent and a preservative are desirably added to the external application preparation for skin of the present invention. In the present embodiment, the pH adjusting agent contains citric acid hydrate and sodium citrate hydrate, but, for example, lactic acid, malic acid, phosphoric acid, carbonic acid, tartaric acid, or a salt thereof. Other pH adjusters may be used. In the present embodiment, the preservative contains methyl paraoxybenzoate and propyl paraoxybenzoate, but other preservatives such as butyl paraoxybenzoate and phenoxyethanol may be used.
Further, as oils and fats to be blended in general creams, vegetable oils such as olive oil and soybean oil, higher fatty acids such as stearic acid, waxes such as beeswax and the like may be blended.
下記の試験において、皮膚外用塗布剤の有効性及び再発抑制効果を評価した。なお、実施例１〜４及び比較例１〜３で用いた皮膚外用塗布剤は、それぞれ表１に記載の処方に従い、以下の工程によって得た。
まず、Ａ成分及びＢ成分をそれぞれ７０〜８０℃で加温溶解した。そして、撹拌しながらＡ成分にＢ成分を徐々に加えて乳化した後、撹拌しながら冷却することによってクリーム剤を得た。
In the following tests, the efficacy and the recurrence inhibitory effect of the skin external application preparation were evaluated. The external application agents for skin used in Examples 1 to 4 and Comparative Examples 1 to 3 were obtained by the following steps according to the formulations shown in Table 1, respectively.
First, the component A and the component B were each dissolved by heating at 70 to 80 ° C. Then, the B component was gradually added to the A component while stirring to emulsify, and then cooled while stirring to obtain a cream.
実施例１及び比較例１〜３の試験方法及び評価方法は以下に示す同一の方法により行った。
＜試験準備＞
・マウスの準備
試験は、アトピー性皮膚炎モデルマウスを用いて行った。このモデルマウスはＮＣマウスと呼ばれるマウスであり、アレルゲンによって、人のアトピー性皮膚炎と類似したアトピー性皮膚炎様症状を発症することから、皮膚炎のモデルマウスとして用いられている。詳しくは、８週齢のＮＣ／ＮｇａＴｎｄＣｒｌｊマウスを、麻酔下で胸部、腹部、及び背部を電気バリカン及び除毛クリームを用いて剃毛して用いた。
・感作物質の調製
ピクリルクロライド（2,4,6-trinitrochlorobenzene）を５％（ｗ／ｖ）の濃度となるよう、エタノールとアセトンの混合液（体積割合４：１）に溶解して感作物質を調製した。
・惹起物質の調製
ピクリルクロライド（2,4,6-trinitrochlorobenzene）を１％（ｗ／ｖ）の濃度となるよう、加温しながら食用オリーブ油に溶解して惹起物質を調製した。
＜処置開始＞
・感作
剃毛翌々日に、マウスを麻酔下において、感作物質を１５０μＬ／匹の液量で、胸腹部及び両足の裏に塗布することにより感作した。感作日を試験０日目とした。
・皮膚炎の誘発
試験４日目、１１日目、１８日目（薬剤投与の前々日）、２７日（最終の薬剤投与日の翌日）に誘発を行った。誘発前日にマウスの背部を剃毛し、誘発日に麻酔下で、惹起物質を１５０μＬ／匹の液量で背部に塗布することで、皮膚炎を誘発した。
・薬剤の投与
感作２０日目から２６日目まで、１日１回、７日間連続で、背部皮膚に１匹あたり１００ｍｇの実施例１及び比較例１〜３の各皮膚外用塗布剤を塗布した。
＜評価方法＞
皮膚炎の重症度を表２〜４に示す皮膚炎スコアに基づいて評価し、評点の合計にて結果を比較した。評価は第１９日から第３４日まで毎日行った。感作後の経過日数と皮膚炎スコアを示すグラフを表５に示す。なお、表５に示すそれぞれの値は、約１０例の平均値±標準誤差を表す。
The test method and evaluation method of Example 1 and Comparative Examples 1 to 3 were performed by the same method described below.
<Test preparation>
-Preparation of mice The test was performed using atopic dermatitis model mice. This model mouse is a mouse called an NC mouse, and is used as a model mouse for dermatitis because it develops atopic dermatitis-like symptoms similar to human atopic dermatitis due to allergen. Specifically, 8-week-old NC / NgaTndCrlj mice were used by shaving the chest, abdomen, and back using an electric clipper and a depilatory cream under anesthesia.
・ Preparation of sensitizing substance Picryl chloride (2,4,6-trinitrochlorobenzene) is dissolved in a mixture of ethanol and acetone (volume ratio 4: 1) to a concentration of 5% (w / v) to give a sensitizing agent. A crop was prepared.
Preparation of Inducing Substance Picryl chloride (2,4,6-trinitrochlorobenzene) was dissolved in edible olive oil while heating so as to have a concentration of 1% (w / v) to prepare an inducing substance.
<Start treatment>
Sensitization On the day after shaving, mice were sensitized by applying a sensitizer to the thorax and abdomen and the soles of both feet in a volume of 150 μL / animal under anesthesia. The day of sensitization was defined as the day 0 of the test.
-Induction of dermatitis Induction was carried out on the 4th, 11th and 18th days (two days before the drug administration) and 27th (the day after the last drug administration). Dermatitis was induced by shaving the back of the mouse on the day before the induction and applying the inducer in a volume of 150 μL / animal to the back under anesthesia on the day of the induction.
・ Administration of the drug 100 mg per animal of the skin external preparation of Example 1 and Comparative Examples 1 to 3 was applied to the back skin once a day for 7 consecutive days from the 20th to 26th day of sensitization. did.
<Evaluation method>
The severity of dermatitis was evaluated based on the dermatitis scores shown in Tables 2 to 4, and the results were compared based on the total score. The evaluation was performed every day from the 19th day to the 34th day. Table 5 shows a graph showing the number of days elapsed after sensitization and the dermatitis score. In addition, each value shown in Table 5 represents the average value ± standard error of about 10 cases.
上記結果に示すように、皮膚外用塗布剤の投与期間中は実施例１が比較例１〜３に比べ低いスコアを示し、炎症症状を抑えている。さらに、皮膚外用塗布剤の投与終了後（２７日目）に惹起物質を投与して再度皮膚炎を誘発した際は、比較例２ではスコアが２７日目から２９日目にかけて大きく上昇しているのに対し、実施例１ではスコアの上昇率が抑えられ、低いスコアを維持している。このように、実施例１は皮膚外用塗布剤の投与中及び投与終了後において比較例１〜３よりも有意に低い値を示し、皮膚炎の再発抑制効果の差は明確であった。
また、実施例２〜４で得た皮膚外用塗布剤についても同様の効果がみられる。
As shown in the above results, during the administration period of the external preparation for skin application, Example 1 showed a lower score than Comparative Examples 1 to 3, and suppressed inflammatory symptoms. Furthermore, when the inducer was administered again after the administration of the external preparation for skin application (day 27) to induce dermatitis again, in Comparative Example 2, the score increased significantly from the 27th day to the 29th day. On the other hand, in Example 1, the rate of increase in the score was suppressed, and a low score was maintained. Thus, Example 1 showed significantly lower values than Comparative Examples 1 to 3 during and after the administration of the external preparation for skin application, and the difference in the effect of suppressing the recurrence of dermatitis was clear.
In addition, the same effects can be obtained with the external application preparations for skin obtained in Examples 2 to 4.
Claims (4)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2017126142 | 2017-06-28 | ||
| JP2017126142 | 2017-06-28 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018026854A Division JP2019006757A (en) | 2017-06-28 | 2018-02-19 | Skin external application agent |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020011993A true JP2020011993A (en) | 2020-01-23 |
| JP6796342B2 JP6796342B2 (en) | 2020-12-09 |
Family
ID=65028518
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018026854A Pending JP2019006757A (en) | 2017-06-28 | 2018-02-19 | Skin external application agent |
| JP2019181614A Active JP6796342B2 (en) | 2017-06-28 | 2019-10-01 | Topical skin application |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018026854A Pending JP2019006757A (en) | 2017-06-28 | 2018-02-19 | Skin external application agent |
Country Status (1)
| Country | Link |
|---|---|
| JP (2) | JP2019006757A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE112021000742T5 (en) | 2020-01-28 | 2022-11-10 | Denso Corporation | Rotating electrical machine |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005200329A (en) * | 2004-01-14 | 2005-07-28 | Shiseido Co Ltd | Skin care medicine preparation for external use |
| JP2005350379A (en) * | 2004-06-09 | 2005-12-22 | Ikeda Mohandou:Kk | Method for stabilizing prednisolone valerate acetate and excellently stable skin care preparation for external use comprising prednisolone valerate acetate |
| JP2006265135A (en) * | 2005-03-23 | 2006-10-05 | Shiseido Co Ltd | Skin care composition |
| JP2011068691A (en) * | 2011-01-05 | 2011-04-07 | Shiseido Co Ltd | Emulsified preparation for external skin care |
-
2018
- 2018-02-19 JP JP2018026854A patent/JP2019006757A/en active Pending
-
2019
- 2019-10-01 JP JP2019181614A patent/JP6796342B2/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005200329A (en) * | 2004-01-14 | 2005-07-28 | Shiseido Co Ltd | Skin care medicine preparation for external use |
| JP2005350379A (en) * | 2004-06-09 | 2005-12-22 | Ikeda Mohandou:Kk | Method for stabilizing prednisolone valerate acetate and excellently stable skin care preparation for external use comprising prednisolone valerate acetate |
| JP2006265135A (en) * | 2005-03-23 | 2006-10-05 | Shiseido Co Ltd | Skin care composition |
| JP2011068691A (en) * | 2011-01-05 | 2011-04-07 | Shiseido Co Ltd | Emulsified preparation for external skin care |
Non-Patent Citations (1)
| Title |
|---|
| 杉林 堅次, DRUG DELIVERY SYSTEM, vol. 31, no. 3, JPN6020029968, July 2016 (2016-07-01), pages 201 - 209, ISSN: 0004324835 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE112021000742T5 (en) | 2020-01-28 | 2022-11-10 | Denso Corporation | Rotating electrical machine |
Also Published As
| Publication number | Publication date |
|---|---|
| JP6796342B2 (en) | 2020-12-09 |
| JP2019006757A (en) | 2019-01-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6337071B2 (en) | Skin preparation for external use | |
| JP2023086619A (en) | emulsion composition | |
| RU2690659C2 (en) | Topical compositions containing corticosteroid | |
| JP6666068B2 (en) | External composition | |
| TWI794222B (en) | Use of composition for preparing drug for treating sleep isturbance | |
| CN113056257A (en) | Semisolid oil-based pharmaceutical composition containing pirfenidone for tissue repair | |
| JP2015530380A (en) | Composition for treating psoriasis | |
| JP6796342B2 (en) | Topical skin application | |
| EP3411014B1 (en) | New topical compositions comprising usnic acid and their use in therapy | |
| JPWO2018230733A1 (en) | Topical skin | |
| JP7313111B2 (en) | Sebum secretion stimulator and composition for external use | |
| RU2225208C1 (en) | Pharmaceutical composition eliciting anti-inflammatory and anti-allergic effect | |
| JP7299683B2 (en) | Skin topical composition | |
| JP7446711B2 (en) | Skin external composition | |
| EP3104839A1 (en) | Topical formulations of heparin | |
| AU2020227426A1 (en) | External preparation for vascular abnormality treatment | |
| JP2024048695A (en) | External composition for treatment of dermatitis | |
| EP4403164A1 (en) | Gel composition for prevention or treatment of atopic dermatitis | |
| WO2019002367A1 (en) | Topical compositions for the treatment of dermatological diseases | |
| JP2000239157A (en) | Agent for external use for skin | |
| JP6084579B2 (en) | Oil-in-water cream composition containing tacrolimus | |
| KR102723936B1 (en) | Skin external composition comprising badger oil | |
| RU2742879C1 (en) | Pharmaceutical composition for the treatment of psoriasis | |
| JP7329910B2 (en) | Skin topical composition | |
| JP2024048659A (en) | External composition for treatment of dermatitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20191001 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200814 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200923 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20200923 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20201030 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20201109 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6796342 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |